Related Experiment Videos
Insights
Left ventricular hypertrophy (LVH) is the heart adapting to high blood pressure, but it increases risks for heart problems and sudden death. Research is exploring how LVH can be reversed with medication.
Area of Science:
- Cardiology
- Pathophysiology
- Molecular Biology
Context:
- Left ventricular hypertrophy (LVH) is a common cardiac adaptation to pressure overload, particularly in hypertensive diseases.
- While initially adaptive, LVH can progress to heart failure.
- Epidemiological studies link LVH to increased cardiovascular morbidity and mortality.
Purpose:
- To summarize the adaptive and maladaptive aspects of left ventricular hypertrophy.
- To highlight the associated cardiovascular risks and mortality.
- To introduce emerging research on the regression of LVH with pharmacologic interventions.
Summary:
- Left ventricular hypertrophy (LVH) is the heart's structural response to increased afterload, maintaining function until decompensation occurs.
- LVH is associated with significant risks, including cardiovascular events, ischemic disease, arrhythmias, and sudden death.
- Mechanisms underlying LVH and its potential regression via specific pharmacologic therapies are areas of active investigation.
Impact:
- Understanding LVH mechanisms can lead to targeted therapies for hypertensive heart disease.
- Identifying patients at high risk for LVH complications is crucial for preventative cardiology.
- Research into LVH regression may offer novel treatment strategies to improve cardiac outcomes and reduce mortality.
Abstract:
Left ventricular hypertrophy is an adaptive structural cardiac response to the afterload imposed by the hypertensive (and other pressure overload) diseases. As such, it maintains a stable cardiac performance until further adaptation is no longer possible, and then cardiac failure supervenes. Offsetting this "beneficial" effect is a distinct risk demonstrated epidemiologically by a greater number of cardiovascular morbid and mortal events, more severe ischemic disease, cardiac dysrhythmias, and sudden death. The precise mechanisms are just beginning to be elucidated. Other new and intriguing areas related to ventricular hypertrophy include its regression with certain forms of pharmacologic therapy and not others. This problem is also being investigated further at this time.